×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US MEA Diabetes Market

ID: MRFR/HC/11468-HCR
200 Pages
Rahul Gotadki
October 2025

US Diabetes Market Research Report By Type (Type 1, Type 2, Gestational diabetes), By Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test, others), By Devices (Blood glucose monitoring devices, Diabetes management devices, others) and By Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery, others) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US MEA Diabetes Market Infographic
×
US MEA Diabetes Market Infographic Full View
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

US MEA Diabetes Market Summary

The US Diabetes market is projected to grow from 1.5 USD Billion in 2024 to 3.2 USD Billion by 2035, reflecting a robust growth trajectory.

Key Market Trends & Highlights

US Diabetes Key Trends and Highlights

  • The US Diabetes market is valued at 1.5 USD Billion in 2024 and is expected to reach 3.2 USD Billion by 2035.
  • The market is anticipated to grow at a compound annual growth rate (CAGR) of 7.13% from 2025 to 2035.
  • The increasing prevalence of diabetes in the United States is driving market expansion and innovation.
  • Growing adoption of advanced diabetes management technologies due to rising health awareness is a major market driver.

Market Size & Forecast

2024 Market Size 1.5 (USD Billion)
2035 Market Size 3.2 (USD Billion)
CAGR (2025-2035) 7.13%

Major Players

AstraZeneca, Merck, Eli Lilly, Medtronic, Dexcom, Boehringer Ingelheim, Novo Nordisk, Insulet, Johnson and Johnson, Amgen, Roche, Tandem Diabetes Care, Sanofi, Abbott, GSK

Market Segment Insights

US Diabetes Market Segment Insights

US Diabetes Market Segment Insights

Diabetes Market Type Insights  

Diabetes Market Type Insights  

The US Diabetes Market is evolving with various types of diabetes playing integral roles in shaping its overall landscape. In recent years, the classification of diabetes has gained significant attention, particularly Type 1, Type 2, and Gestational diabetes. Type 1 diabetes, often diagnosed in children and young adults, is an autoimmune condition that results in the body's inability to produce insulin. This type has prompted increasing focus on Research and Development initiatives aimed at improving treatment options and management strategies.

Conversely, Type 2 diabetes, which is more prevalent among adults and linked to obesity and lifestyle choices, is a major concern in the United States due to its growth trend and impact on public health. As awareness surrounding lifestyle changes continues to propagate, Type 2 diabetes management strategies are gaining traction among healthcare professionals and patients alike, contributing to a change in treatment approaches and accessibility to diabetes care.

Gestational diabetes represents a temporary condition that occurs during pregnancy, impacting both maternal and fetal health. The rising incidence of this condition has led to heightened medical attention and intervention strategies, as effective management helps prevent long-term health issues for both mother and child. The healthcare industry acknowledges the significance of managing gestational diabetes effectively, as it can lead to increased risks of developing Type 2 diabetes later in life. This aspect has resulted in growing demand for comprehensive screening and education programs targeting expectant mothers.

The US Diabetes Market segmentation reflects both the complexity of diabetes types and the corresponding healthcare responses required for effective management. Each type underscores unique risk factors and management strategies, influencing market dynamics considerably. Additionally, the gravity of the diabetes epidemic in the US has galvanized local institutions and healthcare systems to address these challenges through various initiatives, from public awareness campaigns to technological advancements in diabetes management tools. The statistics surrounding diabetes indicate a necessity for ongoing investment in medical solutions and patient education, which is crucial for improving outcomes across all types. 

Diabetes Market Test Insights  

Diabetes Market Test Insights  

The Test segment within the US Diabetes Market plays a crucial role in managing diabetes and monitoring blood glucose levels. With an increasing prevalence of diabetes, effective testing methods such as Random blood sugar test and Fasting blood sugar test have gained significant attention, as they provide immediate insights into a patient's glucose levels, aiding in timely medical decisions. The Oral glucose tolerance test is notable for its ability to diagnose insulin resistance and prediabetes, making it an essential tool in early detection. Additionally, the Initial glucose challenge test holds importance for screening pregnant women, ensuring maternal and fetal health.

Other tests also contribute to the comprehensive monitoring landscape, offering varied methodologies tailored to individual patient needs. The US Diabetes Market revenue is driven by an increasing awareness of diabetes management, led by healthcare initiatives focusing on early diagnosis and lifestyle influences. However, challenges such as accessibility and affordability of testing methods persist. Overall, the US Diabetes Market segmentation demonstrates vast opportunities, particularly in enhancing testing accuracy and broadening access to these vital diabetes management tools, reflecting ongoing growth trends in this sector.

Diabetes Market Devices Insights  

Diabetes Market Devices Insights  

The Devices segment of the US Diabetes Market plays a crucial role in improving the quality of life for millions of individuals living with diabetes. This segment comprises various options, including innovative blood glucose monitoring devices and diabetes management devices, which are essential tools for effective disease control. Blood glucose monitoring devices are critical as they enable patients to track their glucose levels closely, facilitating timely insulin administration and lifestyle adjustments. Diabetes management devices contribute significantly to the adherence to treatment protocols, ensuring patients can manage their condition effectively.

The growing prevalence of diabetes across the United States, fueled by lifestyle factors and an aging population, drives the demand for these devices. Furthermore, advancements in technology, such as glucose monitoring patches and remote health monitoring systems, enhance patient outcomes and engagement, making devices more user-friendly and accessible. Overall, the Devices segment is characterized by continuous innovation and adaptation to patient needs, showcasing its significance within the broader US Diabetes Market landscape. The market's dynamics also present opportunities for further growth as demand for personalized healthcare solutions and connected devices increases among the population.

Diabetes Market Treatment Insights  

Diabetes Market Treatment Insights  

The Treatment segment of the US Diabetes Market plays a crucial role in managing diabetes, focusing on various methods to ensure patient wellness and control blood sugar levels. Medications are pivotal, as they enable millions of patients to manage their conditions effectively, enhancing their quality of life. Insulin therapy stands out as a dominant approach, particularly for Type 1 diabetes, providing essential hormone supplementation that patients need. Transplantation, while less common, offers hope to those with severe diabetes complications, demonstrating advancements in medical approaches.

Bariatric surgery is increasingly recognized for its dual benefit of weight loss and diabetes management, significantly improving metabolic outcomes for individuals with obesity-related diabetes. Collectively, these elements contribute to the growing US Diabetes Market revenue, driven by increasing awareness, rising diabetes prevalence, and ongoing Research and Development in treatment options. The US Diabetes Market segmentation showcases a diverse landscape that offers numerous opportunities for innovation and improved patient care, aligning with health initiatives focused on managing chronic diseases.

Get more detailed insights about US MEA Diabetes Market
Request Free Sample

Key Players and Competitive Insights

The US Diabetes Market is characterized by a strong competitive landscape driven by a significant prevalence of diabetes and a growing emphasis on innovative treatment options. With millions of individuals affected by diabetes, the market has attracted numerous pharmaceutical companies, each striving to capture a share through differentiated products, effective marketing strategies, and strong distribution channels. Key players in this sector invest heavily in research and development to bring forth new therapies, ranging from insulin products to oral medications and combination therapies.
As the demand for diabetes management solutions rises, market participants are continuously adapting to shifting healthcare trends, regulatory challenges, and the evolving needs of patients and healthcare providers. AstraZeneca has established a formidable presence within the US Diabetes Market by offering a range of innovative medications that address the management of Type 2 diabetes. The company's strengths lie in its robust research and development pipeline, allowing it to consistently introduce new products that cater to diverse patient needs.
AstraZeneca's focus on patient-centric solutions, including medications that not only control blood sugar but also provide cardiovascular benefits, has enhanced its reputation in the market. The company also emphasizes collaborations with healthcare professionals and organizations to improve diabetes care, further solidifying its position. With a commitment to leveraging advances in technology for diabetes management, AstraZeneca remains a key player, dedicated to addressing the challenges faced by patients living with diabetes in the US. Merck brings a wealth of experience to the US Diabetes Market, with a portfolio that includes key products designed to enhance diabetes management.
The company's flagship diabetes medication has gained traction among healthcare providers and patients alike, owing to its efficacy and safety profile. Merck's strengths are underscored by its continual investment in clinical research, which supports the expanded use of its products and enhances its market presence. Additionally, Merck has executed strategic mergers and acquisitions to bolster its capabilities, allowing it to tap into new therapeutic areas and expand its product offerings.
In a landscape where customer loyalty and trust play significant roles, Merck's established brand and comprehensive support programs further enhance its competitive edge in the diabetes segment, ensuring it meets the diverse needs of patients across the US.

Key Companies in the US MEA Diabetes Market include

Industry Developments

The US Diabetes Market has seen various developments recently. Notably, in September 2023, Eli Lilly received FDA approval for a new diabetes drug, enhancing its portfolio in the highly competitive landscape. Additionally, in August 2023, Dexcom announced the launch of its latest continuous glucose monitoring system, which is expected to improve patient engagement and management. 

The market has also been impacted by Eli Lilly's partnership with Medtronic to integrate their technologies aimed at streamlining diabetes care. Over the past few years, the market valuation has seen significant growth, with Novo Nordisk, for instance, reporting a substantial uptick in revenue due to its innovative insulin products. Noteworthy mergers and acquisitions in this space include Boehringer Ingelheim acquiring a stake in a digital health startup in July 2023, marking a strategic move towards digitalizing diabetes management solutions. 

The American Diabetes Association has also emphasized the need for better access to diabetes medications, leading to ongoing discussions on pricing and coverage, reflecting broader healthcare reform efforts initiated in 2021 that continue to shape this market.

Market Segmentation

Diabetes Market Test Outlook

  • Random blood sugar test
  • Fasting blood sugar test
  • Oral glucose tolerance test
  • Initial glucose challenge test
  • others

Diabetes Market Devices Outlook

  • Blood glucose monitoring devices
  • Diabetes management devices
  • others

Diabetes Market Treatment Outlook

  • Medications
  • Insulin therapy
  • Transplantation
  • Bariatric surgery
  • others

Report Scope

Report Attribute/Metric Details
Market Size 2018 1.42(USD Billion)
Market Size 2024 1.5(USD Billion)
Market Size 2035 3.2(USD Billion)
Compound Annual Growth Rate (CAGR) 7.131% (2025 - 2035)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled AstraZeneca, Merck, Eli Lilly, Medtronic, Dexcom, Boehringer Ingelheim, Novo Nordisk, Insulet, Johnson  and  Johnson, Amgen, Roche, Tandem Diabetes Care, Sanofi, Abbott, GSK
Segments Covered Type, Test, Devices, Treatment
Key Market Opportunities Telehealth diabetes management solutions, Continuous glucose monitoring technology, Personalized diabetes treatment plans, Education and support services expansion, Digital health apps for self-management
Key Market Dynamics rising diabetes prevalence, increasing healthcare costs, advancements in treatment technologies, growing demand for remote monitoring, government initiatives for diabetes management
Countries Covered US
Leave a Comment

FAQs

What is the projected market size of the US Diabetes Market in 2024?

The US Diabetes Market is expected to be valued at 1.5 billion USD in 2024.

What will be the market size of the US Diabetes Market by 2035?

By 2035, the market is projected to reach 3.2 billion USD.

What is the expected CAGR for the US Diabetes Market from 2025 to 2035?

The expected CAGR for the US Diabetes Market during this period is 7.131%.

Which type of diabetes has the highest market value in 2024?

In 2024, Type 2 diabetes has the highest market value at 0.8 billion USD.

What is the market size projection for Type 1 diabetes by 2035?

The market size for Type 1 diabetes is expected to reach 1.1 billion USD by 2035.

Who are the key players in the US Diabetes Market?

Major players in the market include AstraZeneca, Merck, Eli Lilly, and Medtronic among others.

What is the size of the Gestational diabetes market in 2024?

The Gestational diabetes market is valued at 0.2 billion USD in 2024.

What market growth rate can be expected for Type 2 diabetes from 2025 to 2035?

The Type 2 diabetes segment is anticipated to experience significant growth aligned with the overall market CAGR of 7.131%.

Which region shows promising growth opportunities for the US Diabetes Market?

The entire US region holds promise for growth opportunities due to increasing prevalence and awareness of diabetes.

How does the competition landscape look in the US Diabetes Market?

The competition is strong with notable companies like Novo Nordisk and Johnson & Johnson competing vigorously in key segments.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓